Through independent innovation, minimally invasive medical products designed in my country have begun to be exported abroad
June 7 is the day of the college entrance examination. The cardiac surgery department led by Professor Meng Xu of Beijing Anzhen Hospital The minimally invasive stent valve team also experienced a major test and successfully completed two cases of transapical minimally invasive stent aortic valve implantation. This is the first time this surgery has been performed in China since the domestic J-Valve stent valve was officially launched. Two 80-year-old patients underwent surgery. One had poor heart function and the other suffered from chronic obstructive pulmonary disease and extremely poor lung function. Neither could tolerate conventional cardiopulmonary bypass heart surgery.
Zhang Haibo, chief physician of cardiovascular surgery at Beijing Anzhen Hospital, said that traditional heart surgery generally requires opening the chest to stop the heart and maintain human body function through extracorporeal circulation. For patients, such surgery leaves The trauma is relatively large. Minimally invasive technology only requires opening a small hole of 2-3 cm in the human body, without opening the chest, keeping the heart beating, and without relying on extracorporeal circulation, and directly implants a valve with a diameter of 21-27 mm into the heart.
The J-Valve stent valve implanted this time is a valve independently designed in China with a unique programmable release positioning key function. It has independent intellectual property rights and is a rare medical device in my country in recent years. One of the innovative technologies is a milestone in the development of minimally invasive valve technology in my country. This product is not only the first minimally invasive interventional valve launched through the transapical approach in China, but also the only aortic valve implantation product in the world that is suitable for both aortic valve stenosis and insufficiency.
Zhang Haibo said that in the past 10 years, the source of high-tech heart valve devices has mainly relied on imports from abroad. Not only are the prices very high, but they also have to go through many procedures. Nowadays, the corresponding core indicators of this valve produced in China are comparable to those of previous imported products. It is worth mentioning that this is the only valve product whose technology has been exported abroad in reverse. Production has already begun in Canada and will also begin in Europe. This means that this "Chinese heart" has been recognized by the international community and further It has enhanced my country's world influence in the field of minimally invasive valves.
In the competition with international medical device companies, domestic medical devices have always been at the back. When domestic medical devices have completed the accumulation from scratch, even if they start from following, as long as they persist in independent innovation, they can gradually achieve the leap from "0 to 1", enter the leading formation, and achieve a "counterattack."